A platinum containing anticancer medication.
Information about Oxaliplatin
Liver safety of Oxaliplatin
Oxaliplatin therapy is associated with a low rate of transient serum aminotransferase elevations, but is commonly associated with sinusoidal and vascular injury to the liver which can lead to sinusoidal obstruction syndrome and to nodular regenerative hyperplasia with noncirrhotic portal hypertension.
Mechanism of action of Oxaliplatin
Oxaliplatin (ox al" i pla' tin) is a cisplatin analog with a tetravalent platinum molecule which is referred to as a platinum coordination complex. Oxaliplatin acts as an alkylating agent causing cross linking between and within DNA strands leading to inhibition of DNA, RNA and protein synthesis and the triggering of programmed cell death, mostly in rapidly dividing cells.
FDA approval information for Oxaliplatin
Oxaliplatin was approved for use in cancer chemotherapy in the United States in 2002.
Clinical use of Oxaliplatin
Its current indications are colorectal carcinoma and it is usually administered in combination with other agents such as 5-fluorouracil (5-FU), irinotecan or capecitabine.
Dosage and administration for Oxaliplatin
Oxaliplatin is available in an aqueous solution for injection in 50, 100 and 200 mg vials in generic forms and under the brand name Eloxatin.
Side effects of Oxaliplatin
The platinum based antineoplastic agents have similar toxicities, including nausea and vomiting, diarrhea, bone marrow suppression, as well as neuro-, oto- and nephrotoxicity. They are also mutagenic, teratogenic and carcinogenic, and their use has been associated with an increased risk of secondary leukemias.